1. Cell death induced by N-(4-hydroxyphenyl)retinamide in human epidermal keratinocytes is modulated by TGF-beta and diminishes during the progression of squamous cell carcinoma.
- Author
-
Davies M, Paterson IC, Ganapathy A, and Prime SS
- Subjects
- Antineoplastic Agents pharmacology, Blotting, Northern, Blotting, Western, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Cell Cycle drug effects, Cell Line, Cell Proliferation drug effects, Disease Progression, Dose-Response Relationship, Drug, Drug Synergism, Flow Cytometry, Gene Expression drug effects, Humans, Keratinocytes cytology, Keratinocytes metabolism, Signal Transduction drug effects, Time Factors, Transforming Growth Factor beta genetics, Transforming Growth Factor beta metabolism, Transforming Growth Factor beta1 genetics, Transforming Growth Factor beta1 metabolism, Transforming Growth Factor beta1 pharmacology, Transforming Growth Factor beta2 genetics, Transforming Growth Factor beta2 metabolism, Transforming Growth Factor beta2 pharmacology, Apoptosis drug effects, Fenretinide pharmacology, Keratinocytes drug effects, Transforming Growth Factor beta pharmacology
- Abstract
It has been demonstrated that the chemopreventive agent N-(4-hydroxyphenyl)retinamide (4-HPR) induces apoptotic cell death, but recent data has suggested that late stage/recurrent tumours lose their response to 4-HPR-induced cell death by mechanisms that are unknown. Our study investigated the ability of 4-HPR to induce cell death in keratinocyte cell lines that represent different stages of carcinogenesis and the role of TGF-beta signalling in the induction of cell death by 4-HPR. We show that treatment of the immortalised keratinocyte cell line HaCaT with 10(-5) M 4-HPR induced cell death by apoptosis and caused an accumulation of cells in the G0/G1 phase of the cell cycle. Using a genetically related series of human skin keratinocytes derived from HaCaT that reflect tumour progression and metastasis in vivo, we demonstrate that 4-HPR-induced cell death and apoptosis is attenuated in the more aggressive tumour cell lines but that a reduced level of response is retained. Response to TGF-beta-induced growth inhibition was also reduced in the more aggressive cell lines. Treatment of HaCaT cells with 4-HPR induced TGF-beta2 expression and an increase in the amount of active TGF-beta in the culture medium. The inhibition of TGF-beta signalling attenuated 4-HPR-induced apoptosis and both TGF-beta1 and TGF-beta2 potentiated 4-HPR-induced apoptosis and enhanced 4-HPR-induced growth inhibition. Our results demonstrate that loss of response to 4-HPR correlates with a loss of response to the growth inhibitory effects of TGF-beta and that adjuvant therapies that upregulate TGF-beta may enhance the chemopreventive effects of 4-HPR., (Copyright 2006 Wiley-Liss, Inc.)
- Published
- 2006
- Full Text
- View/download PDF